PS
Prakritee Sandilya
About Prakritee Sandilya
Data last updated:
Prakritee Sandilya has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Urovision Diagnostics & Research Centre Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Urovision Diagnostics & Research Centre Private Limited at ₹10.75 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 05 Sep 2016 | 2001 | ₹10.75 Cr (FY 2024) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Prakritee Sandilya
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prakritee Sandilya
Prakritee Sandilya has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Urovision Diagnostics & Research Centre Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Urovision Diagnostics & Research Centre Private Limited at ₹10.75 Cr (FY 2024).
Prakritee Sandilya is associated with 1 company as Director, including Urovision Diagnostics & Research Centre Private Limited (₹10.75 Cr).
Prakritee Sandilya has expertise in General Business.
Prakritee Sandilya has 10 years in corporate governance.
By reported revenue, the largest current company of Prakritee Sandilya is Urovision Diagnostics & Research Centre Private Limited, with revenue of ₹10.75 Cr (FY 2024).
Prakritee Sandilya currently holds positions at 1 company: Urovision Diagnostics & Research Centre Private Limited (₹10.75 Cr).